Introduction {#S0001}
============

The roll-out of antiretroviral treatment in South Africa has led to positive outcomes that have been documented in several studies.^[@CIT0001]--[@CIT0003]^ Significant reductions in AIDS-related morbidity and mortality have been documented already.^[@CIT0004]--[@CIT0006]^ Unfortunately, up to 25% of patients discontinue their initial antiretroviral treatment regimen because of treatment failure, non-compliance or low adherence, as well as to adverse effects.^[@CIT0007]--[@CIT0010]^ Adverse effects have been shown to affect both the quality of life and the survival of patients, and it follows that it is important to describe these effects. In doing so, the findings of this study will contribute to the identification of adverse or side effects that should be targeted for monitoring by clinicians and for creating awareness of these effects amongst patients. The purpose of this study, therefore, was to investigate the causes of death in a sample of adult HIV-infected patients on antiretroviral treatment at Thembisa Hospital in Johannesburg, South Africa.

Significance of the study {#S20002}
-------------------------

This study investigated the side effects associated with mortality in a sample of adult HIV-infected patients on antiretroviral treatment. The findings of this study will contribute to the identification of side effects that should be targeted for monitoring by clinicians and for creating awareness of these effects amongst patients.

Ethical considerations {#S0003}
======================

The approval to conduct this study was obtained from the Medunsa Campus Research and the Ethics Committee of the University of Limpopo. Permission to access the patients' records was requested and obtained from Management at the hospital.

Methods {#S0004}
=======

A retrospective study was conducted by examining the charts of 498 adult patients treated from January 2004 to December 2006 at the antiretroviral clinic of a regional hospital in Johannesburg. A data collection form was used to collate both sociodemographic and clinical data, including the age and sex of the patients as well as the documented side effects, whether they had died or were still alive, the recorded cause of death, the stage of the infection, the duration of treatment, and the regimen they took. Descriptive statistics and cross-tabulation were used in the analysis of data. All statistical analyses were performed using SPSS software (version 17.0; SPSS, Chicago, IL, USA).

Results {#S0005}
=======

The sample comprised mostly female patients (71.7%), whose mean age was 37.7 ± 11.6, ranging from 18 to 77 years. The greater number of the patients was South African citizens, with only 2.2% citizens of other Southern African countries such as the Democratic Republic of Congo (1), Malawi (1), Mozambique (1), Zambia (1), and Zimbabwe (7). The majority of patients had completed a high school level of education (75.1%) and were unemployed (80.3%). With regard to their lifestyle, few of them smoked (6.7%), or consumed alcoholic drinks (8%). From the onset of enrolment into the antiretroviral treatment, 29.9% had been on anti-tuberculosis treatment.

Their immunological status was considered as poor because most of them (97.2%) had CD4 counts \< 200 copies/mL. The majority (57%) of them were afflicted by severe immune depression because they met the WHO (World Health Organisation) clinical Stage 3 and Stage 4. Most of the patients had been prescribed the regimen made of stavudine, lamivudine, and nevirapine or efavirenz; two of them (0.4%) were on the second line regimen made of zidovudine, didanosine, and lopinavir--ritonavir ([Table 1](#T0001){ref-type="table"}). At least one side effect was documented in 82.1% of patients. The ten most documented side effects ([Table 2](#T0002){ref-type="table"}) were skin rashes (62.9%), peripheral neuropathy (48.4%), headaches (38.2%), chest pain (21.9%), coughing (21.7%), anaemia (21.5%), diarrhoea (19.3%), vomiting (16.7%), dizziness (15.3%), and lactic acidosis (11.2%). Of these side effects, lactic acidosis was associated with a number of deaths. Overall, a mortality rate of 3.6%, or 18 deaths during the 2-year study period, was recorded. Although the cause of death was undetermined in 11.1% of patients, 50.0% and 38.9% of deaths were ascribed in the patients' records, respectively to tuberculosis and lactic acidosis ([Figure 1](#F0001){ref-type="fig"}). The odd ratios of dying from lactic acidosis was 5.6 \[(95% CI: 2.1--15.1); *p* = 0.0001\]; compared to 4 \[(95% CI: 1.5--10.4); *p* = 0.002\] for tuberculosis. However, all the 18 patients that died were amongst the 284 that had severe immune suppression. Moreover, 11 of the 18 deaths had a CD4 cells count ≤ 100 copies/mL ([Table 3](#T0003){ref-type="table"}). Although most of the deaths occurred between the first 6 months to the end of the first year of treatment ([Figure 3](#F0003){ref-type="fig"}), deaths associated with lactic acidosis continued to occur even after 18 months on treatment ([Figure 4](#F0004){ref-type="fig"}). Of those who died, the majority had been initiated on antiretroviral treatment late (they were classified as WHO Stage 3), they were mostly female, and aged 30--39 ([Figure 2](#F0002){ref-type="fig"}).
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###### 

Sociodemographic and baseline data of HIV-infected patients from Thembisa Hospital 2004--2006.

  Variables                                Frequency   \%
  ---------------------------------------- ----------- ------
  **Gender**                                           
  Female                                   *354*       71.1
  Male                                     144         28.9
  **Age group** (years)                                
  18--29                                   70          14.1
  30--39                                   244         49.0
  40--49                                   134         26.9
  50 +                                     50          10.0
  **Level of education**                               
  Grades 0--7                              108         21.7
  Grades 8--12                             374         75.1
  Tertiary level                           16          3.2
  **Employment status**                                
  Unemployed                               400         80.3
  Employed                                 98          19.7
  **Lifestyle**                                        
  Alcohol drinking status                  40          8.0
  Smoking status                           34          6.8
  **Type of regimen**                                  
  Regimen 1a                               312         62.7
  Regimen 1b                               184         36.9
  Second line                              2           0.4
  **Tuberculosis (TB) treatment status**               
  On TB treatment                          105         29.9
  Not on TB treatment                      246         70.1
  **WHO clinical stage**                               
  Stage 1                                  45          9.0
  Stage 2                                  169         33.9
  Stage 3                                  239         48.0
  Stage 4                                  45          9.0
  **Viral load (VL) status at baseline**               
  VL ≤ 400                                 8           1.6
  VL \> 400                                478         98.4
  **CD4 count status at baseline**                     
  CD4 \> 200                               14          2.8
  CD4 ≤ 200                                484         97.2

*Source*: Authors' original data

WHO, World Health Organisation.

###### 

Side effects documented in HIV-infected patients at Thembisa Hospital 2004--2006.

  Side effects             Frequency   \%
  ------------------------ ----------- ------
  Skin rashes, itching     313         62.9
  Peripheral neuropathy    241         48.4
  Headache                 190         38.2
  Chest pains              109         21.9
  Coughing                 108         21.7
  Anaemia                  107         21.5
  Diarrhoea                96          19.3
  Nausea or vomiting       83          16.7
  Dizziness                76          15.3
  Lactic acid acidosis     56          11.2
  Heartburn                44          8.8
  Fatigue                  42          8.4
  Loss of appetite         40          8.0
  Bloating                 38          7.6
  Weight loss              37          7.4
  Muscle and joint pains   33          6.6
  Trouble sleeping         25          5.0
  Ringing in ear           20          4.0
  Blurred vision           20          4.0
  Cotrimoxazole allergy    18          3.6

*Source*: Authors' original data

###### 

Clinical stage of HIV-infected patients that died at Thembisa Hospital 2004--2006.

  Period             Cause             Variables   WHO stage   Baseline CD4 counts values        
  ------------------ ----------------- ----------- ----------- ---------------------------- ---- -----
  6th--12th month    Unknown           Patient 1   Yes         \-                           6    \-
                                       Patient 2   Yes         \-                           \-   100
                     Lactic acidosis   Patient 1   \-          Yes                          31   \-
                                       Patient 2   Yes         \-                           \-   131
                     Tuberculosis      Patient 1   Yes         \-                           \-   193
                                       Patient 2   Yes         \-                           \-   196
                                       Patient 3   \-          Yes                          1    \-
                                       Patient 4   \-          Yes                          9    \-
                                       Patient 5   Yes         \-                           38   \-
                                       Patient 6   Yes         \-                           \-   169
                                       Patient 7   Yes         \-                           71   \-
  12th--18th month   Lactic acidosis   Patient 1   Yes         \-                           3    \-
                                       Patient 2   Yes         \-                           16   \-
                                       Patient 3   Yes         \-                           \-   130
                                       Patient 4   Yes         \-                           66   \-
                     Tuberculosis      Patient 1   \-          Yes                          85   \-
                                       Patient 2   Yes         \-                           84   \-
  18th--24th month   Lactic acidosis   Patient 1   \-          Yes                          31   \-

*Source*: Authors' original data

Discussion {#S0006}
==========

The prevalence of adverse events documented was 82.1%. This figure is comparable to the figure of 89% reported at another hospital from the same province.^[@CIT0011]^ This finding suggests that health-care providers of antiretroviral therapy have been doing good work by recording the adverse effects noticed. It further corroborates the view that side effects are common during antiretroviral therapy in South Africa in accordance to reports elsewhere.^[@CIT0012]--[@CIT0014]^ The most common effects, skin rashes, peripheral neuropathy, and lactic acidosis have been consistently reported in patients taking the regimen containing nevirapine and/or stavudine. At the time of the study, almost all patients were prescribed the regimen that contained stavudine. The range of adverse effects documented was similar to that reported previously by other investigators.^[@CIT0011]--[@CIT0014]^ Moreover, the impact of adverse effects on adherence to antiretroviral treatment is well established;^[@CIT0015],\ [@CIT0016]^ in this study, their impact on mortality has been assessed.

With regard to mortality, 3.6% had died during the 2 years covered by the study. This finding is consistent but lower than the figures reported in the literature.^[@CIT0017]--[@CIT0020]^ In fact, it has been reported that 8% -- 26% of patients die within the first year of antiretroviral treatment.^[@CIT0021]^ Furthermore, the findings of this study concur with previous studies in that most deaths occurred during the initial months of treatment.^[@CIT0022],\ [@CIT0023]^ Data from this study show that the majority of patients sought treatment when they were at an advanced clinical stage of the disease because 57% of them had been classified as WHO Stage 3 and Stage 4 patients ([Table 3](#T0003){ref-type="table"}). This finding is consistent with previous reports about the influence of late initiation of antiretroviral treatement.^[@CIT0001],\ [@CIT0003],\ [@CIT0004],\ [@CIT0017],\ [@CIT0023]^ In addition, 29.9% of them were afflicted by tuberculosis. Overall, 50% and 38.8% of deaths reported in this study were ascribed to tuberculosis and lactic acidosis respectively. Although the odds of dying were high for both conditions, because all patients that died had been severely immune-compromised, it is plausible that this situation also contributed to the deaths. Furthermore, although deaths ascribed to tuberculosis decreased from a majority (63.6%) status by the end of the first year of treatment to zero towards the end of the second year, deaths ascribed to lactic acidosis increased during the same periods from 18.2% to 66.7% ([Figure 3](#F0003){ref-type="fig"}). This finding suggests that, although deaths caused by tuberculosis could be halted when tuberculosis is cured, the danger from lactic acidosis cannot be averted easily. Stavudine is known for its association with lactic acidosis, and consequently this finding lends support to the decision to remove stavudine as a component of the first line regimen in South Africa.^[@CIT0007],\ [@CIT0013],\ [@CIT0025],\ [@CIT0026]^ Indeed, as from April 2010, the new guidelines have replaced stavudine with tenofovir in the first line regimen.^[@CIT0027]^ The rationale for this proposition is that lactic acidosis is insidious and produces ordinary symptoms such as nausea, vomiting, and abdominal pain. These symptoms may be overlooked by clinicians, which make it difficult for them to take the necessary steps to save patients' lives. The distribution of deaths by age showed that a number of deaths were recorded in the age group of 30--39 (66%) followed by the age group 40--49 (28%). No deaths were recorded in patients who were 50 years or older, which suggests that older patients may have had a better survival rate because of their self-efficacy, or because they started the treatment early enough, but the rationale for the enhanced survival could not be established in this study.^[@CIT0021],\ [@CIT0022],\ [@CIT0024]--[@CIT0028]^
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In addition, because of limitations relating to the design of this cross-sectional study, it is unclear whether the 11.1% of deaths that were undetermined were caused by other infections, or adverse effects that were not documented. Similarly, it is not known whether the non-prescribed medicines taken by some patients could have contributed to the occurrence of adverse events; this has been reported.^[@CIT0029]^ Further prospective studies, including reported data on adverse effects, are needed to assess the impact of the involvement of other non-prescribed medicines on the deaths attributed to side effects such as lactic acidosis. Previous studies demonstrated the need for such studies.^[@CIT0007],\ [@CIT0017],\ [@CIT0029]^ Professional health-care workers play an important role in the provision of antiretroviral therapy,^[@CIT0030]^ and as such there is a need to keep them updated on new developments and to train them on the implementation of pharmacovigilance concepts in their clinical practice.

Conclusion {#S0007}
==========

In addition to tuberculosis, side effects in particular, lactic acidosis was the other main cause of death in patients treated at the study site. These findings suggest that patients who take regimens containing drugs that cause lactic acidosis should be closely monitored when the first complaints suggesting lactic acidosis, are reported or noticed.
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